107 related articles for article (PubMed ID: 37946409)
1. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
3. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
[TBL] [Abstract][Full Text] [Related]
5. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
6. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
8. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
[TBL] [Abstract][Full Text] [Related]
9.
Francis JH; Gobin YP; Brannon AR; Swartzwelder CE; Berger MF; Mandelker DL; Walsh MF; Dunkel IJ; Abramson DH
Ophthalmol Sci; 2021 Sep; 1(3):100042. PubMed ID: 36247821
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
[TBL] [Abstract][Full Text] [Related]
11. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
12. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
Front Oncol; 2021; 11():736769. PubMed ID: 34868925
[TBL] [Abstract][Full Text] [Related]
16. Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ciriaco N; Zamora E; Escrivá-de-Romaní S; Miranda Gómez I; Jiménez Flores J; Saura C; Sloane H; Starus A; Fredebohm J; Georgieva L; Speight G; Jones F; Ramón Y Cajal S; Espinosa-Bravo M; Peg V
Ther Adv Med Oncol; 2022; 14():17588359221139601. PubMed ID: 36479470
[TBL] [Abstract][Full Text] [Related]
17. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract][Full Text] [Related]
20. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
Bregni G; Pretta A; Senti C; Acedo Reina E; Vandeputte C; Trevisi E; Gkolfakis P; Kehagias P; Deleporte A; Van Laethem JL; Vergauwe P; Van den Eynde M; Deboever G; Janssens J; Demolin G; Holbrechts S; Clausse M; De Grez T; Peeters M; D'Hondt L; Geboes K; Besse-Hammer T; Rothé F; Flamen P; Hendlisz A; Sclafani F
Acta Oncol; 2022 Oct; 61(10):1223-1229. PubMed ID: 35866544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
